SPDL1 and renal cell carcinoma: Soluble PD-L1 (sPD-L1) has been tested in patients with renal cell carcinoma or melanoma prior to, and at two time points during, treatment with Nivolumab; a progressive or stable disease was associated with an increase in sPD-L1 [35].